Blastomycosis Market By Formulation (Tablets, Ointment, Powder, Liquid), By Drug Type (Azoles, Polyenes, Others), By Distribution Channel (Hospital and Clinical Pharmacy, Online Pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
Blastomycosis is a type of fungal infection caused by the fungus Blastomyces dermatitidis, which grows in wood and soil. Spores of Blastomyces enter the body through air, when inhaled, thus it mainly affects the lung and causes pneumonia. Fungi are spread through the bloodstream to other parts of the body. The symptoms of blastomycosis are often similar to the symptoms of other lung infections and can include cough, night sweats, muscle aches or joint pain, weight loss, chest pain, and fatigue.
When blastomycosis infection is spread in the skin, treatments such as azole, allylamines, echinocandins, and polyenes can be given in mild to moderate cases of blastomycosis infection.
Major factors driving the growth of the blastomycosis market include a rise in the development of new medicine for the treatment of blastomycosis infection, an increase in the prevalence rate of chronic diseases such as pneumonia, tuberculosis, a non-infectious pulmonary disease that have led to increases in a number of blastomycosis patients, and high adoption of azoles for the treatment of blastomycosis. Further, growth in the incidence and prevalence rate of infectious diseases and the rise in the population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market.
For instance, according to the Centers for Disease Control and Prevention, 7,860 tuberculosis (TB) cases were reported in the U.S. in 2021 (a rate of 2.4 per 100,000 persons). In the U.S., up to 13 million people live with latent TB infection. This has led to an increase in the number of blastomycosis patients, which increases the demand for blastomycosis treatment. Hence, such factors drive the growth of blastomycosis treatment.
For instance, according to World Health Organization (WHO), 34.8 million people were living with HIV worldwide in 2021 and 650,000 people died of HIV-related illnesses worldwide in 2021. According to this 1.5 million people acquiring HIV in 2021. Hence, these HIV patients are more vulnerable to blastomycosis, owing to weak immunity to HIV.
However, unfavorable reimbursements as well as complications such as high costs of medicine and drugs for blastomycosis are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for blastomycosis medicine manufacturers worldwide in the future.
Furthermore, the healthcare business is projected to witness growth owing to a rise in immunocompromised patients, a rise in the prevalence of acquired immunodeficiency syndrome (AIDS), that are more vulnerable to blastomycosis, and a boost in the growth of the blastomycosis market. In addition, an increase in the discovery & development of safe and effective medicine for blastomycosis and a rise in awareness regarding the use of azoles for the treatment of blastomycosis drive the growth of the blastomycosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
Moreover, a rise in R&D investments, an increase in azoles-assisted clinical research studies, a significant rise in the capital income in developed countries, and a surge in key strategies such as acquisition, collaboration, and product launch, adopted by key players strengthen the demand for blastomycosis in the market.
For instance, in June 2021, Celon Laboratories Pvt. Ltd. announced the launch of AMFIGHT, an amphotericin B emulsion, used in the treatment of fungal infection. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany — lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase the production of this medication, Celon developed an alternative, an emulsion-based formulation. The launch of AMFIGHT will help the company to strengthen its anti-fungal product portfolio. This type of product launch boosts the growth of the blastomycosis market.
The blastomycosis market is segmented on the basis of formulation, drug type, distribution channel, and region. On the basis of formulation, the market is classified into tablets, ointment, powder, and liquid. On the basis of drug type, the market is classified into azoles, polyenes, and others. Depending on the distribution channel, it is fragmented into hospital & clinical pharmacy, online pharmacy, and retail pharmacy. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Abbott Laboratories, Astellas Pharma Inc., Celon Laboratories Pvt. Ltd., Cipla Ltd, GlaxoSmithKline plc, Johnson and Johnson, Merck KGaA, Pfizer Inc., Sanofi S.A., and Sun Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blastomycosis market analysis from 2021 to 2031 to identify the prevailing blastomycosis market opportunities.
Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
An in-depth analysis of the blastomycosis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes an analysis of the regional as well as global blastomycosis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
Azoles
Polyenes
Others
By Distribution Channel
Hospital and Clinical Pharmacy
Online Pharmacy
Retail Pharmacy
By Formulation
Tablets
Ointment
Powder
Liquid
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
Key Market Players
Pfizer Inc.
Sanofi
Merck and Company
GSK
johnson and johnson md&d
Abbott Laboratories
CELON LABORATORIES LIMITED
Sun Pharmaceuticals Ltd
Astellas Pharma Inc.
Cipla Ltd
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: BLASTOMYCOSIS MARKET, BY FORMULATION
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Tablets
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.3 Ointment
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
- 4.4 Powder
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market share analysis by country
- 4.5 Liquid
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market share analysis by country
- CHAPTER 5: BLASTOMYCOSIS MARKET, BY DRUG TYPE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Azoles
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3 Polyenes
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
- 5.4 Others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country
- CHAPTER 6: BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital and Clinical Pharmacy
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
- 6.3 Online Pharmacy
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
- 6.4 Retail Pharmacy
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country
- CHAPTER 7: BLASTOMYCOSIS MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Formulation
- 7.2.3 North America Market size and forecast, by Drug Type
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Key market trends, growth factors and opportunities
- 7.2.5.1.2 Market size and forecast, by Formulation
- 7.2.5.1.3 Market size and forecast, by Drug Type
- 7.2.5.1.4 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Key market trends, growth factors and opportunities
- 7.2.5.2.2 Market size and forecast, by Formulation
- 7.2.5.2.3 Market size and forecast, by Drug Type
- 7.2.5.2.4 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Key market trends, growth factors and opportunities
- 7.2.5.3.2 Market size and forecast, by Formulation
- 7.2.5.3.3 Market size and forecast, by Drug Type
- 7.2.5.3.4 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Formulation
- 7.3.3 Europe Market size and forecast, by Drug Type
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Key market trends, growth factors and opportunities
- 7.3.5.1.2 Market size and forecast, by Formulation
- 7.3.5.1.3 Market size and forecast, by Drug Type
- 7.3.5.1.4 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Key market trends, growth factors and opportunities
- 7.3.5.2.2 Market size and forecast, by Formulation
- 7.3.5.2.3 Market size and forecast, by Drug Type
- 7.3.5.2.4 Market size and forecast, by Distribution Channel
- 7.3.5.3 UK
- 7.3.5.3.1 Key market trends, growth factors and opportunities
- 7.3.5.3.2 Market size and forecast, by Formulation
- 7.3.5.3.3 Market size and forecast, by Drug Type
- 7.3.5.3.4 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Key market trends, growth factors and opportunities
- 7.3.5.4.2 Market size and forecast, by Formulation
- 7.3.5.4.3 Market size and forecast, by Drug Type
- 7.3.5.4.4 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Key market trends, growth factors and opportunities
- 7.3.5.5.2 Market size and forecast, by Formulation
- 7.3.5.5.3 Market size and forecast, by Drug Type
- 7.3.5.5.4 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Key market trends, growth factors and opportunities
- 7.3.5.6.2 Market size and forecast, by Formulation
- 7.3.5.6.3 Market size and forecast, by Drug Type
- 7.3.5.6.4 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Formulation
- 7.4.3 Asia-Pacific Market size and forecast, by Drug Type
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Key market trends, growth factors and opportunities
- 7.4.5.1.2 Market size and forecast, by Formulation
- 7.4.5.1.3 Market size and forecast, by Drug Type
- 7.4.5.1.4 Market size and forecast, by Distribution Channel
- 7.4.5.2 India
- 7.4.5.2.1 Key market trends, growth factors and opportunities
- 7.4.5.2.2 Market size and forecast, by Formulation
- 7.4.5.2.3 Market size and forecast, by Drug Type
- 7.4.5.2.4 Market size and forecast, by Distribution Channel
- 7.4.5.3 Australia
- 7.4.5.3.1 Key market trends, growth factors and opportunities
- 7.4.5.3.2 Market size and forecast, by Formulation
- 7.4.5.3.3 Market size and forecast, by Drug Type
- 7.4.5.3.4 Market size and forecast, by Distribution Channel
- 7.4.5.4 South Korea
- 7.4.5.4.1 Key market trends, growth factors and opportunities
- 7.4.5.4.2 Market size and forecast, by Formulation
- 7.4.5.4.3 Market size and forecast, by Drug Type
- 7.4.5.4.4 Market size and forecast, by Distribution Channel
- 7.4.5.5 Rest of Asia-Pacific
- 7.4.5.5.1 Key market trends, growth factors and opportunities
- 7.4.5.5.2 Market size and forecast, by Formulation
- 7.4.5.5.3 Market size and forecast, by Drug Type
- 7.4.5.5.4 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Formulation
- 7.5.3 LAMEA Market size and forecast, by Drug Type
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Key market trends, growth factors and opportunities
- 7.5.5.1.2 Market size and forecast, by Formulation
- 7.5.5.1.3 Market size and forecast, by Drug Type
- 7.5.5.1.4 Market size and forecast, by Distribution Channel
- 7.5.5.2 South Africa
- 7.5.5.2.1 Key market trends, growth factors and opportunities
- 7.5.5.2.2 Market size and forecast, by Formulation
- 7.5.5.2.3 Market size and forecast, by Drug Type
- 7.5.5.2.4 Market size and forecast, by Distribution Channel
- 7.5.5.3 Saudi Arabia
- 7.5.5.3.1 Key market trends, growth factors and opportunities
- 7.5.5.3.2 Market size and forecast, by Formulation
- 7.5.5.3.3 Market size and forecast, by Drug Type
- 7.5.5.3.4 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Key market trends, growth factors and opportunities
- 7.5.5.4.2 Market size and forecast, by Formulation
- 7.5.5.4.3 Market size and forecast, by Drug Type
- 7.5.5.4.4 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Pfizer Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Sanofi
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Merck and Company
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 GSK
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 johnson and johnson md&d
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Abbott Laboratories
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 CELON LABORATORIES LIMITED
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Sun Pharmaceuticals Ltd
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Astellas Pharma Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Cipla Ltd
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 2. BLASTOMYCOSIS MARKET FOR TABLETS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 3. BLASTOMYCOSIS MARKET FOR TABLETS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 4. BLASTOMYCOSIS MARKET FOR OINTMENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 5. BLASTOMYCOSIS MARKET FOR OINTMENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 6. BLASTOMYCOSIS MARKET FOR POWDER, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 7. BLASTOMYCOSIS MARKET FOR POWDER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 8. BLASTOMYCOSIS MARKET FOR LIQUID, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 9. BLASTOMYCOSIS MARKET FOR LIQUID, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 10. GLOBAL BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 11. BLASTOMYCOSIS MARKET FOR AZOLES, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 12. BLASTOMYCOSIS MARKET FOR AZOLES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 13. BLASTOMYCOSIS MARKET FOR POLYENES, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 14. BLASTOMYCOSIS MARKET FOR POLYENES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 15. BLASTOMYCOSIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 16. BLASTOMYCOSIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 17. GLOBAL BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 18. BLASTOMYCOSIS MARKET FOR HOSPITAL AND CLINICAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 19. BLASTOMYCOSIS MARKET FOR HOSPITAL AND CLINICAL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 20. BLASTOMYCOSIS MARKET FOR ONLINE PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 21. BLASTOMYCOSIS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 22. BLASTOMYCOSIS MARKET FOR RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 23. BLASTOMYCOSIS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 24. BLASTOMYCOSIS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 25. NORTH AMERICA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 26. NORTH AMERICA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 27. NORTH AMERICA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 28. NORTH AMERICA BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 29. U.S. BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 30. U.S. BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 31. U.S. BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 32. CANADA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 33. CANADA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 34. CANADA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 35. MEXICO BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 36. MEXICO BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 37. MEXICO BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 38. EUROPE BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 39. EUROPE BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 40. EUROPE BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 41. EUROPE BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 42. GERMANY BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 43. GERMANY BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 44. GERMANY BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 45. FRANCE BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 46. FRANCE BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 47. FRANCE BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 48. UK BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 49. UK BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 50. UK BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 51. ITALY BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 52. ITALY BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 53. ITALY BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 54. SPAIN BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 55. SPAIN BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 56. SPAIN BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 57. REST OF EUROPE BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 58. REST OF EUROPE BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 59. REST OF EUROPE BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 60. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 61. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 62. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 63. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 64. CHINA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 65. CHINA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 66. CHINA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 67. INDIA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 68. INDIA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 69. INDIA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 70. AUSTRALIA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 71. AUSTRALIA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 72. AUSTRALIA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 73. SOUTH KOREA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 74. SOUTH KOREA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 75. SOUTH KOREA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 76. REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 77. REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 78. REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 79. LAMEA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 80. LAMEA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 81. LAMEA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 82. LAMEA BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 83. BRAZIL BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 84. BRAZIL BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 85. BRAZIL BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 86. SOUTH AFRICA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 87. SOUTH AFRICA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 88. SOUTH AFRICA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 89. SAUDI ARABIA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 90. SAUDI ARABIA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 91. SAUDI ARABIA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 92. REST OF LAMEA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 93. REST OF LAMEA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 94. REST OF LAMEA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
- TABLE 95.PFIZER INC.: COMPANY SNAPSHOT
- TABLE 96.PFIZER INC.: OPERATING SEGMENTS
- TABLE 97.PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 98.PFIZER INC.: NET SALES
- TABLE 99.PFIZER INC.: KEY STRATERGIES
- TABLE 100.SANOFI: COMPANY SNAPSHOT
- TABLE 101.SANOFI: OPERATING SEGMENTS
- TABLE 102.SANOFI: PRODUCT PORTFOLIO
- TABLE 103.SANOFI: NET SALES
- TABLE 104.SANOFI: KEY STRATERGIES
- TABLE 105.MERCK AND COMPANY: COMPANY SNAPSHOT
- TABLE 106.MERCK AND COMPANY: OPERATING SEGMENTS
- TABLE 107.MERCK AND COMPANY: PRODUCT PORTFOLIO
- TABLE 108.MERCK AND COMPANY: NET SALES
- TABLE 109.MERCK AND COMPANY: KEY STRATERGIES
- TABLE 110.GSK: COMPANY SNAPSHOT
- TABLE 111.GSK: OPERATING SEGMENTS
- TABLE 112.GSK: PRODUCT PORTFOLIO
- TABLE 113.GSK: NET SALES
- TABLE 114.GSK: KEY STRATERGIES
- TABLE 115.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
- TABLE 116.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
- TABLE 117.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
- TABLE 118.JOHNSON AND JOHNSON MD&D: NET SALES
- TABLE 119.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
- TABLE 120.ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 121.ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 122.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 123.ABBOTT LABORATORIES: NET SALES
- TABLE 124.ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 125.CELON LABORATORIES LIMITED: COMPANY SNAPSHOT
- TABLE 126.CELON LABORATORIES LIMITED: OPERATING SEGMENTS
- TABLE 127.CELON LABORATORIES LIMITED: PRODUCT PORTFOLIO
- TABLE 128.CELON LABORATORIES LIMITED: NET SALES
- TABLE 129.CELON LABORATORIES LIMITED: KEY STRATERGIES
- TABLE 130.SUN PHARMACEUTICALS LTD: COMPANY SNAPSHOT
- TABLE 131.SUN PHARMACEUTICALS LTD: OPERATING SEGMENTS
- TABLE 132.SUN PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
- TABLE 133.SUN PHARMACEUTICALS LTD: NET SALES
- TABLE 134.SUN PHARMACEUTICALS LTD: KEY STRATERGIES
- TABLE 135.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
- TABLE 136.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
- TABLE 137.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
- TABLE 138.ASTELLAS PHARMA INC.: NET SALES
- TABLE 139.ASTELLAS PHARMA INC.: KEY STRATERGIES
- TABLE 140.CIPLA LTD: COMPANY SNAPSHOT
- TABLE 141.CIPLA LTD: OPERATING SEGMENTS
- TABLE 142.CIPLA LTD: PRODUCT PORTFOLIO
- TABLE 143.CIPLA LTD: NET SALES
- TABLE 144.CIPLA LTD: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.BLASTOMYCOSIS MARKET SEGMENTATION
- FIGURE 2.BLASTOMYCOSIS MARKET,2021-2031
- FIGURE 3.BLASTOMYCOSIS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.BLASTOMYCOSIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.BLASTOMYCOSIS MARKET,BY FORMULATION,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TABLETS BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OINTMENT BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF POWDER BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF LIQUID BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 17.BLASTOMYCOSIS MARKET,BY DRUG TYPE,2021(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF AZOLES BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF POLYENES BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 21.BLASTOMYCOSIS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL AND CLINICAL PHARMACY BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY BLASTOMYCOSIS MARKET,2021-2031(%)
- FIGURE 25.BLASTOMYCOSIS MARKET BY REGION,2021
- FIGURE 26.U.S. BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 27.CANADA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 28.MEXICO BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 29.GERMANY BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 30.FRANCE BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 31.UK BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 32.ITALY BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 33.SPAIN BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 34.REST OF EUROPE BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 35.CHINA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 36.INDIA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 37.AUSTRALIA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 38.SOUTH KOREA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 39.REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 40.BRAZIL BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 41.SOUTH AFRICA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 42.SAUDI ARABIA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 43.REST OF LAMEA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
- FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 48.COMPETITIVE DASHBOARD
- FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 50.PFIZER INC..: NET SALES ($MILLION)
- FIGURE 51.SANOFI.: NET SALES ($MILLION)
- FIGURE 52.MERCK AND COMPANY.: NET SALES ($MILLION)
- FIGURE 53.GSK.: NET SALES ($MILLION)
- FIGURE 54.JOHNSON AND JOHNSON MD&D.: NET SALES ($MILLION)
- FIGURE 55.ABBOTT LABORATORIES.: NET SALES ($MILLION)
- FIGURE 56.CELON LABORATORIES LIMITED.: NET SALES ($MILLION)
- FIGURE 57.SUN PHARMACEUTICALS LTD.: NET SALES ($MILLION)
- FIGURE 58.ASTELLAS PHARMA INC..: NET SALES ($MILLION)
- FIGURE 59.CIPLA LTD.: NET SALES ($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook